243 related articles for article (PubMed ID: 26667803)
1. Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery?
Sechi LA; Colussi GL; Novello M; Uzzau A; Catena C
Horm Metab Res; 2015 Dec; 47(13):1000-6. PubMed ID: 26667803
[TBL] [Abstract][Full Text] [Related]
2. Primary Aldosteronism: Present and Future.
Funder JW
Vitam Horm; 2019; 109():285-302. PubMed ID: 30678860
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Outcomes with Surgical and Medical Management of Primary Aldosteronism.
Wachtel H; Fraker DL
Curr Cardiol Rep; 2021 Jun; 23(7):89. PubMed ID: 34081226
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism.
Katabami T; Fukuda H; Tsukiyama H; Tanaka Y; Takeda Y; Kurihara I; Ito H; Tsuiki M; Ichijo T; Wada N; Shibayama Y; Yoshimoto T; Ogawa Y; Kawashima J; Sone M; Inagaki N; Takahashi K; Fujita M; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Kamemura K; Otsuki M; Fujii Y; Yamamoto K; Ogo A; Yanase T; Suzuki T; Naruse M;
J Hypertens; 2019 Jul; 37(7):1513-1520. PubMed ID: 31145370
[TBL] [Abstract][Full Text] [Related]
5. Primary Aldosteronism and the Role of Mineralocorticoid Receptor Antagonists for the Heart and Kidneys.
Cohen JB; Bancos I; Brown JM; Sarathy H; Turcu AF; Cohen DL
Annu Rev Med; 2023 Jan; 74():217-230. PubMed ID: 36375469
[TBL] [Abstract][Full Text] [Related]
6. Recent progress in the diagnosis and treatment of primary aldosteronism.
Yoshida Y; Shibata H
Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
[TBL] [Abstract][Full Text] [Related]
7. Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Lales G; Mitas C; Doumas M
Curr Pharm Des; 2018; 24(46):5508-5516. PubMed ID: 30854950
[TBL] [Abstract][Full Text] [Related]
8. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.
Morimoto S; Ichihara A
Hypertens Res; 2020 Aug; 43(8):744-753. PubMed ID: 32424201
[TBL] [Abstract][Full Text] [Related]
9. Personalized Treatment of Patients With Primary Aldosteronism.
Obeid H; Chen Cardenas SM; Khairi S; Turcu AF
Endocr Pract; 2023 Jun; 29(6):484-490. PubMed ID: 36273684
[TBL] [Abstract][Full Text] [Related]
10. Advances in Medical Treatment of Primary Aldosteronism.
Li YJ; Ji ZG; Wen J
Chin Med Sci J; 2023 Mar; 38(1):49-56. PubMed ID: 36642703
[TBL] [Abstract][Full Text] [Related]
11. Primary Aldosteronism: Practical Approach to Diagnosis and Management.
Byrd JB; Turcu AF; Auchus RJ
Circulation; 2018 Aug; 138(8):823-835. PubMed ID: 30359120
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism.
Satoh M; Maruhashi T; Yoshida Y; Shibata H
Hypertens Res; 2019 Jun; 42(6):817-824. PubMed ID: 30948836
[TBL] [Abstract][Full Text] [Related]
13. Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
Tezuka Y; Turcu AF
Front Endocrinol (Lausanne); 2021; 12():625457. PubMed ID: 33841329
[TBL] [Abstract][Full Text] [Related]
14. [Primary aldosteronism: from diagnosis to therapy in clinical practice].
Vetri M; Cassaniti L; Francese GM; Gulizia MM
G Ital Cardiol (Rome); 2021 Apr; 22(4):319-326. PubMed ID: 33783452
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers to Guide Medical Therapy in Primary Aldosteronism.
Hundemer GL; Leung AA; Kline GA; Brown JM; Turcu AF; Vaidya A
Endocr Rev; 2024 Jan; 45(1):69-94. PubMed ID: 37439256
[TBL] [Abstract][Full Text] [Related]
16. Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment.
Hundemer GL
Curr Cardiol Rep; 2019 Jul; 21(9):93. PubMed ID: 31352525
[TBL] [Abstract][Full Text] [Related]
17. Surgery decreases the long-term incident stroke risk in patients with primary aldosteronism.
Chang YH; Chung SD; Wu CH; Chueh JS; Chen L; Lin PC; Lin YH; Huang KH; Wu VC; Chu TS;
Surgery; 2020 Feb; 167(2):367-377. PubMed ID: 31676114
[TBL] [Abstract][Full Text] [Related]
18. Association Between Acute Fall in Estimated Glomerular Filtration Rate After Treatment for Primary Aldosteronism and Long-Term Decline in Renal Function.
Kobayashi H; Abe M; Nakamura Y; Takahashi K; Fujita M; Takeda Y; Yoneda T; Kurihara I; Itoh H; Tsuiki M; Wada N; Ichijo T; Katabami T; Ogawa Y; Kawashima J; Yoshimoto T; Sone M; Inagaki N; Watanabe M; Kamemura K; Matsuda Y; Izawa S; Tanabe M; Tanabe A; Suzuki T; Naruse M;
Hypertension; 2019 Sep; 74(3):630-638. PubMed ID: 31327258
[TBL] [Abstract][Full Text] [Related]
19. THERAPY OF ENDOCRINE DISEASE: Medical treatment of primary aldosteronism.
Lechner B; Lechner K; Heinrich D; Adolf C; Holler F; Schneider H; Beuschlein F; Reincke M
Eur J Endocrinol; 2019 Oct; 181(4):R147-R153. PubMed ID: 31299637
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of primary aldosteronism treatment on patients with primary aldosteronism and chronic kidney disease.
Nakano Y; Murakami M; Hara K; Fukuda T; Horino M; Takeuchi A; Niitsu Y; Shiba K; Tsujimoto K; Komiya C; Yokoyama M; Ikeda K; Yoshimoto T; Fujii Y; Yamada T
Clin Endocrinol (Oxf); 2023 Mar; 98(3):323-331. PubMed ID: 36367014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
